Department of Urology, Faculty of Medicine, Okan University Hospital, Istanbul, Turkey.
Department of Urology, Adana Seyhan State Hospital, Adana, Turkey.
J Laparoendosc Adv Surg Tech A. 2022 Apr;32(4):355-359. doi: 10.1089/lap.2021.0174. Epub 2021 May 6.
We aim to directly compare the feasibility and safety of extended pelvic lymph node dissection (PLND) during transperitoneal robotic-assisted radical prostatectomy (Tp-RARP) and extraperitoneal laparoscopic radical prostatectomy (Ep-LRP). We retrospectively identified the prospectively maintained database records of 162 patients diagnosed with prostate cancer (PC) who underwent Ep-LRP or Tp-RARP with extended PLND. Patients with risk of nodal metastases over 5% according to Briganti nomogram received extended PLND. All data analyzed in this study were based on the documentation in our PC database including age, body mass index, Charlson comorbidity index score, preoperative prostate-specific antigen, history of abdominal surgery, biopsy Gleason score, total operation time, postoperative pelvic drainage time, pathological results, lymph node yield (LNY), percentage lymph node involvement (%LNI), and perioperative complications. Patients were followed up for biochemical recurrence in the postoperative period. Eighty-two of the 162 enrolled patients were in group 1 (Ep-LRP+PLND) and 80 were in group 2 (Tp-RARP+PLND). There were no statistically significant differences between the groups regarding preoperative demographics and clinical characteristics. The median LNY was 17 (range 8-27) and 17.5 (range 10-29) in groups 1 and 2, respectively, and no statistically significant difference was found. There was no significant difference between the groups in terms of biochemical recurrence-free survival with mean follow-up of 44.8 months after radical surgery. Our results support the view that extended PLND through the Ep-LRP approach is a feasible and safe procedure without compromising oncological efficacy compared with a similar template attempted during Tp-RARP. Clinical Trial Registration number is 01/21-2.
我们旨在直接比较经腹腔机器人辅助根治性前列腺切除术(Tp-RARP)和经腹腔腹腔镜根治性前列腺切除术(Ep-LRP)中扩展盆腔淋巴结清扫术(PLND)的可行性和安全性。我们回顾性地确定了 162 例经 Ep-LRP 或 Tp-RARP 行扩展 PLND 的前列腺癌(PC)患者的前瞻性维护数据库记录。根据 Briganti 列线图,有 5%以上淋巴结转移风险的患者接受了扩展 PLND。本研究中分析的所有数据均基于我们的 PC 数据库中的记录,包括年龄、体重指数、Charlson 合并症指数评分、术前前列腺特异性抗原、腹部手术史、活检 Gleason 评分、总手术时间、术后盆腔引流时间、病理结果、淋巴结产量(LNY)、淋巴结受累百分比(%LNI)和围手术期并发症。患者在术后随访期接受生化复发检查。162 名入组患者中,82 名患者分在第 1 组(Ep-LRP+PLND),80 名患者分在第 2 组(Tp-RARP+PLND)。两组患者术前人口统计学和临床特征无统计学差异。第 1 组和第 2 组的中位 LNY 分别为 17(范围 8-27)和 17.5(范围 10-29),无统计学差异。两组患者的生化无复发生存率无显著差异,根治性手术后平均随访时间为 44.8 个月。我们的结果支持这样一种观点,即通过 Ep-LRP 途径进行扩展 PLND 是一种可行且安全的方法,与在 Tp-RARP 中尝试类似模板相比,不会影响肿瘤学疗效。临床试验注册号为 01/21-2。